UNSPSC 51422425: Hydrocortisone acetate

This classification denotes a therapeutic glucocorticoid with the molecular formula C23H32O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3X7931PO74, chemically known as pregn-4-ene-3,20-dione,11beta,17alpha,21-trihydroxy-,21 acetate but more generally known as hydrocortisone acetate, which bears US NIH Compound Identifier 3641. European Medicines Agency schedules Hydrocortisone acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02562MIG.

UNSPSC 51422425 Hydrocortisone acetate is a Commodity code for a corticosteroid pharmaceutical product, but the recent state and local procurement activity under this code shows a significant mismatch: the single identified opportunity from Seminole County, Florida (IFB 60459723LAS, posted June 30, 2026) solicits Naloxone and Safe Drug Deactivation Systems, not hydrocortisone acetate. Naloxone is an opioid antagonist used for overdose reversal, and drug deactivation systems are disposal or neutralization equipment — neither product aligns with the code's nominal scope. The Seminole County procurement is structured as a competitive IFB with quarterly deliveries, a two-year initial term plus one-year renewal option, and E-Verify and drug-free workplace compliance requirements. The code shows minimal recent activity under its intended pharmaceutical classification.

Seminole County is the only recent issuing body visible under this code. The procurement is limited to a single Florida county with deliveries to the Seminole County Community Health Building in Sanford. Given that the lone opportunity under this code addresses opioid response and drug management rather than hydrocortisone acetate, the code does not currently reflect state and local purchase patterns aligned with its therapeutic classification. Business development professionals should note that either Seminole County applied an incorrect UNSPSC classification to a naloxone and drug deactivation procurement, or the code itself carries miscategorized opportunities in state and local sourcing systems. Practitioners pursuing pharmaceutical supply contracts with state and local health agencies should cross-check coding classifications against the actual products being solicited before committing resources to RFP cycles.